KELOWNA, British Columbia, - (http://www.financialnewsmedia.com
News Alert) - Marapharm Ventures Inc. (OTCQB: MRPHF) (CSE: MDM) ("Marapharm") announces that it is paying the Nevada Title, Escrow Agent, for full payment and discharge of the first mortgage financing on 5.9 acres located in Apex Industrial Park, Las Vegas, Nevada. In addition Marapharm is paying cash without debt for the previously announced addition of 1.1 adjoining acres.
"We've received several million dollars recently from warrants being exercised by loyal shareholders with more coming in daily, and we decided to pay off our debt, which is this one mortgage. We paid $445,500 USD for the property and financed $309,000. In addition we paid taxes and fees and posted about $100,000 for wet and dry utility bonds. We've also done improvements on the site and have invested more than $100,000 on site and facilities planning. And we've paid for buildings that are to be delivered within 3 weeks and erected for cultivation. The monthly mortgage payments were $2,785.22" said Linda Sampson, Marapharm CEO and she added "paying off a relatively small mortgage and paying $110,000 cash for the 1.1 acres may not sound like a big deal but to us the significance is that we did what we planned to do in terms of reaching our milestones." Read this and more news for Marapharm at: http://financialnewsmedia.com/profiles/mrphf.html
"With more than 50 million adult visitors each year, Las Vegas is the known as the best cannabis play in the world. Marapharm chose Las Vegas and Nevada for its model and for a place we wanted to be for doing business. There's no state corporate income tax, there's no personal income tax, there's City tax concessions, there's excellent State incentives and we are located in a logistical hub of 11 state regions. Further there's an educated and cost effective workforce and a superior telecommunications infrastructure. So we believe that we are in the right place at the right time" says Linda Sampson. Marapharm CEO.
ABOUT MARAPHARM VENTURES INC.
Marapharm has 300,000 square feet of medical marijuana licenses and land and facilities in WA and NV and about two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (Production and Sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com
), the OTC website (http://www.otcmarkets.com
) and Sedar website (http://www.sedar.com
) under the profile for Marapharm Ventures Inc.
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
FOR FURTHER INFORMATION:
or Linda Sampson, CEO, +1-778-583-4476 firstname.lastname@example.org
SOURCE Marapharm Ventures Inc.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated four thousand nine hundred dollars for Marapharm Ventures Inc., Inc. news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Marapharm Ventures Inc.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.